Figure S3: Mass spectra for the NIST mAb standard (a) fully glycosylated (intact), (b) following endoS2 treatment (truncated glycans) and (c) following PNGase F treatment (fully deglycosylated). The inserts are a zoom-in of the
The Herceptin® mAb lots (A, B and C) and NIST mAb reference standard were deglycosylated using PNGase F and digested separately using endo S2 then analysed via linear IM-MS in helium. The measured arrival time distributions (ATDs) were converted to DT CCS He distributions (CCSDs) for the most intense charge states (7). The change in CCS between intact and glycan treated samples was greater (~3.2-3.5%) than the corresponding reduction in mass of ~2%, therefore confirming that glycan removal alters conformation. For all samples there was a decrease in both the width and position of the CCSD plots for charge states 22 + -24 + with endo S2 digestion and PNGase F treatment. The 25 + charge state in particular offered clear differences between the samples, with distinct second conformers and shifts to higher CCS. Samples A and B showed a high degree of similarity across all charge states, both in terms of the charge state distributions presented and the changes in conformation induced upon glycan removal. The NIST standard and sample C, however, presented quite different conformational pictures. In both samples there was clearly a more prominent extended distribution for the 25 + charge state indicative of a more flexible conformational spread; confirmed also by the increase in standard deviation. Figure is 
Figure S7: DT CCSD He plots for fully glycosylated (intact), partially deglycosylated (endo S2 treated) and fully deglycosylated (PNGase F treated) IgG1 mAbs (charge state range 22 + to 25 + ). Data fitted with Gaussians (cumulative fit plotted) and normalised against (IMS area fraction) x (MS peak height fraction). Width of shading around each peak denotes the standard deviation calculated, n=3. An interactive version of this

Figure S13: Typical uptake plot for an example Herceptin® mAb peptide (WESNGQPENN) highlighting the uptake differences between the three sample preparations; fully glycosylated -intact (red), partially deglycosylated -endo S2 treated (blue) and fully deglycosylated -PNGase F treated (green).
Figure S14: Typical uptake plot for an example Waters mAb peptide (HEGLHNHHTEKSLSHSPG) highlighting the uptake differences between the three sample preparations; fully glycosylated -intact (red), partially deglycosylated -endo S2 treated (blue) and fully deglycosylated -PNGase F treated (green).
